Short description
Northwest Biotherapeutics is a biotechnology company focused on developing and commercializing immunotherapy products to treat cancer.
Description
Northwest Biotherapeutics is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company operates in the United States and is incorporated in Delaware, USA. Currently approved cancer treatments are frequently ineffective, can cause undesirable side effects and provide marginal clinical benefits. The Company’s approach in developing cancer therapies utilizes its expertise in the biology of dendritic cells, which are a type of white blood cell that activate the immune system. The Company’s cancer therapies have been demonstrated in clinical trials to significantly extend both time to recurrence and survival, whilst providing a superior quality of life with no debilitating side effects when compared with current therapies.
Last funding
Cannot Access
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Bethesda, Maryland, United States, North America
Founded on
January 1, 1998
Exited on
December 19, 2016
Went public on
December 19, 2016
Stock symbol
NWBO
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$7890 - 12340
Sign in for full access
Investors
Blurry Noaccess
Sign in for full access
Founders
Alton L. Boynton